Want to see JP:2784 full AI Analyst Report?
Alfresa Holdings (2784) Stock Price & Analysis
2784 Stock Chart & Stats
- Day’s Range
- JPY 2,422.00 - JPY 2,469.00
- 52-Week Range
- JPY 2,106.50 - JPY 2,685.50
- Previous Close
- JPY 2,440.00
- Volume
- 617.40K
- Average Volume (3M)
- 385.36K
- Market Cap
- JPY 471.16B
- Enterprise Value
- JPY 227.35B
- Total Cash (Recent Filing)
- JPY 192.07B
- Total Debt (Recent Filing)
- JPY 30.00B
- Price to Earnings (P/E)
- 11.4
- Beta
- 0.47
- Next Earnings
- Nov 09, 2026 (Est.)
- EPS Estimate
- 30.48
- Next Dividend Ex-Date
- Mar 31, 2027
- Dividend Yield
- 2.79%
Bulls Say, Bears Say
Bulls Say
Steady Revenue Growth
Steady revenue growth, with acceleration into 2026, indicates resilient demand across Alfresa’s distribution activities. Continued top-line expansion supports scale benefits, reinforces customer relevance, and provides a durable base for earnings growth even in a low-margin industry.
Conservative Balance Sheet
Very low leverage gives Alfresa meaningful financial flexibility and reduces solvency pressure during weaker operating periods. A growing equity base can support investment, working-capital needs, and shareholder returns while limiting dependence on external financing.
Scaled Distribution Network
A nationwide distribution network and high delivery frequency are important structural assets in pharmaceutical wholesaling. Scale can strengthen customer coverage, support efficient order fulfillment, and deepen the company’s role in the healthcare supply chain over time.
Bears Say
Thin Profit Margins
Thin gross and net margins leave limited room to absorb cost increases, pricing pressure, or operational inefficiencies. Because a small change in expenses can materially affect earnings, profitability remains structurally vulnerable despite steady revenue growth.
Inconsistent Cash Conversion
Volatile operating and free cash flow indicates that reported earnings do not consistently convert into cash. Working-capital swings or uneven investment timing can constrain internally funded growth, weaken capital allocation flexibility, and make financial performance less predictable.
Weakening Operating Efficiency
The decline in EBITDA margin suggests that operating scale has not translated into stronger profitability. Persistently modest returns in this large-asset distribution model could limit earnings resilience and leave future performance sensitive to cost control and pricing discipline.
2784 FAQ
What was Alfresa Holdings’s price range in the past 12 months?
What is Alfresa Holdings’s market cap?
When is Alfresa Holdings’s upcoming earnings report date?
How were Alfresa Holdings’s earnings last quarter?
Is Alfresa Holdings overvalued?
Does Alfresa Holdings pay dividends?
What is Alfresa Holdings’s EPS estimate?
How many shares outstanding does Alfresa Holdings have?
What happened to Alfresa Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Alfresa Holdings?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Alfresa Holdings
Alfresa Holdings Corporation, a Japanese company established in Tokyo in 2003, operates globally through its subsidiaries, specializing in the production, wholesale distribution, marketing, and international trade of pharmaceuticals, diagnostic reagents, and medical equipment. A significant part of its operations involves the wholesale supply of ethical pharmaceuticals, diagnostic reagents, and medical devices to healthcare providers including hospitals, clinics, and dispensing pharmacies. The company also manages the wholesale distribution of self-medication products, such as over-the-counter drugs, nutritional supplements, and health foods, to drugstores and pharmacies. Furthermore, Alfresa is engaged in the manufacturing and commercialization of active pharmaceutical ingredients, various pharmaceuticals, diagnostic reagents, and medical devices, alongside providing contract manufacturing services for pharmaceutical goods. Its medical-related division also encompasses the management of dispensing pharmacies and other associated healthcare activities.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Ryuji Arakawa
- Employees
- 12,525
- Website
- www.alfresa.com
- Address
- Ote Center Building, Tokyo, TY, 100-0004, JP
Alfresa Holdings (2784) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 12 | 0 | 0 |



